Verapamil and its metabolite norverapamil inhibit the Mycobacterium tuberculosis MmpS5L5 efflux pump to increase bedaquiline activity.

Publication Details

Journal
Apollo (University of Cambridge)
Published
2024-12-26
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Verapamil and its metabolite norverapamil inhibit the Mycobacterium tuberculosis MmpS5L5 efflux pump to increase bedaquiline activity.

Apollo (University of Cambridge)
Tuberculosis Research and Epidemiology
article

Verapamil and its metabolite norverapamil inhibit the Mycobacterium tuberculosis MmpS5L5 efflux pump to increase bedaquiline activity.

article en

Abstract

No abstract available for this paper.
Apollo (University of Cambridge)
University of Otago, Wellcome Trust, Royal Society Te Apārangi, Maurice Wilkins Centre for Molecular Biodiscovery, National Institutes of Health, Health Research Council of New Zealand, Marsden Fund, National Institute of Allergy and Infectious Diseases
Zero hunger
Openalex Percentile: Top 48%
Tuberculosis Research and Epidemiology
Open Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Verapamil and its metabolite norverapamil inhibit the Mycobacterium tuberculosis MmpS5L5 efflux pump to increase bedaquiline activity. · Apollo (University of Cambridge) (2024) | TGRS Research Map | TGRS